US Patent Issued to GlaxoSmithKline on July 22 for "(N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide" (California, Connecticut Inventors)

Posted On: 2025-07-23

ALEXANDRIA, Va., July 23 -- United States Patent no. RE50,497, issued on July 22, was assigned to GlaxoSmithKline LLC (Wilmington, Del.).

"(N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide" was invented by Brandon H. Brown (Burlingame, Calif.), Ernest A. Carra (Foster City, Calif.), Jeffrey N. Hemenway (San Mateo, Calif.), Henry Morrison (Dublin, Calif.), Troy Reynolds (San Francisco), Bing Shi (Redwood City, Calif.), Dimitrios Stefanidis (Mountain View, Calif.), Fang Wang (Foster City, Calif.), Matthew Robert Warr (Madison, Conn.), James Andrew Whitney (Guilford, Conn.) and Yan Xin (San Carlos, Calif.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention relates to stabl...

Click here to read full article from source

To read the full article or to get the complete feed from this publication, please Contact Us.

Exclusive

Category

Source

Publication

Location

US Patent Issued to GlaxoSmithKline on July 22 for "(N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide" (California, Connecticut Inventors)